The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction

American Heart Journal

Volumn 163, Issue 4, 2012, Pages 705-713

  Duffy, Danielle ^a   Holmes, Dajuanicia N ^b   Roe, Matthew T ^b   Peterson, Eric D ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE;

AGED; AGED, 80 AND OVER; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MYOCARDIAL INFARCTION; PROGNOSIS; RECURRENCE; RISK FACTORS;

EID: 84860137956     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.01.029     Document Type: Article

References (22)

1. W.E. Boden High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial Am J Cardiol 86 2000 19L 22L
2. P. Barter, A.M. Gotto, and J.C. LaRosa HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310
3. P.M. Ridker, J. Genest, and S.M. Boekholdt HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 376 2010 333 339
4. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
5. J.A. de Lemos, M.A. Blazing, and S.D. Wiviott Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
6. A. Sachdeva, C.P. Cannon, and P.C. Deedwania Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines Am Heart J 157 2009 111 117
7. M.T. Roe, F.S. Ou, and K.P. Alexander Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes Eur Heart J 29 2008 2480 2488
8. J.W. Hoekstra, C.V. Pollack, and M.T. Roe Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: The CRUSADE initiative Acad Emerg Med 9 2002 1146 1155
9. B.G. Hammill, A.F. Hernandez, and E.D. Peterson Linking inpatient clinical registry data to Medicare claims data using indirect identifiers Am Heart J 157 2009 995 1000
10. Special Communication Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
11. M.T. Roe, A.Y. Chen, and L. Thomas Predicting long-term mortality in older patients after non-ST-segment elevation myocardial infarction: the CRUSADE long-term mortality model and risk score Am Heart J 162 2011 875 883
12. A.G. Olsson, G.G. Schwartz, and M. Szarek High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial Eur Heart J 26 2005 890 896
13. G.G. Schwartz High-density lipoprotein cholesterol as a risk factor and target of therapy after acute coronary syndrome Am J Cardiol 104 2009 46E 51E
14. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
15. The AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl Med J 365 2011 2255 2267
16. The AIM-HIGH Investigators The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) Am Heart J 161 2011 471 477
17. The AIM-HIGH Investigators The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) Am Heart J 161 2011 538 543
18. P.J. Barter, M. Caulfield, and M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
19. S.E. Nissen, T. Tsunoda, and E.M. Tuzcu Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
20. R. Waksman, R. Torguson, and K.M. Kent A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J Am Coll Cardiol 55 2010 2727 2735
21. D. Duffy, and D.J. Rader Update on strategies to increase HDL quantity and function Nat Rev Cardiol 6 2009 455 463
22. L.A. Petersen, S. Wright, and S.L. Normand Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database J Gen Intern Med 14 1999 555 558